MIHALOVIC, Michal, Robert PETR, Denisa ODVODYOVÁ, Ivana MALINICOVA, Katerina PILIKOVA, Michal KARPISEK, Jiří JARKOVSKÝ and Zuzana MOTOVSKA. Abstract 13625: Laboratory Markers of Effective Endogenous Fibrinolysis in Intermediate-High-Risk Pulmonary Embolism. In VASCULAR DISEASE AND THROMBOSIS 2023. 2023. ISSN 1346-9843. Available from: https://dx.doi.org/10.1161/circ.148.suppl_1.13625.
Other formats:   BibTeX LaTeX RIS
Basic information
Original name Abstract 13625: Laboratory Markers of Effective Endogenous Fibrinolysis in Intermediate-High-Risk Pulmonary Embolism
Authors MIHALOVIC, Michal, Robert PETR, Denisa ODVODYOVÁ, Ivana MALINICOVA, Katerina PILIKOVA, Michal KARPISEK, Jiří JARKOVSKÝ (203 Czech Republic, belonging to the institution) and Zuzana MOTOVSKA.
Edition VASCULAR DISEASE AND THROMBOSIS 2023, 2023.
Other information
Original language English
Type of outcome Conference abstract
Field of Study 30230 Other clinical medicine subjects
Country of publisher United States of America
Confidentiality degree is not subject to a state or trade secret
WWW URL
Impact factor Impact factor: 3.300 in 2022
RIV identification code RIV/00216224:90249/23:00133232
ISSN 1346-9843
Doi http://dx.doi.org/10.1161/circ.148.suppl_1.13625
Keywords (in Czech) Endogenous Fibrinolysis; High-Risk Pulmonary Embolism;
Keywords in English Endogenous Fibrinolysis; High-Risk Pulmonary Embolism;
Tags FN KV, RIV, user
Tags International impact
Changed by Changed by: Mgr. Michal Petr, učo 65024. Changed: 12/4/2024 12:54.
Abstract
Introduction: Unselected therapy with fibrinolysis in intermediate risk-pulmonary embolism (iPE) is associated with an unacceptable risk of bleeding. Early identification of iPE patients on anticoagulant therapy with ineffective endogenous fibrinolysis (eFL) could optimize treatment-strategy. Aims: The study aims to determine markers of (in)effective eFL in intermediate-risk PE initially on anticoagulant therapy with UFH.
Links
90249, large research infrastructuresName: CZECRIN IV
PrintDisplayed: 23/7/2024 16:13